Professor of Medicine, University of Cincinnati
Missouri United States
Bruce Yacyshyn, MD, is a Professor of Medicine (Gastroenterology) at University Of Cincinnati since March 2009. He is an expert in translational research and has the understanding of the clinical implications of clinical or basic science research. He is a Medical Director at the University of Cincinnati Hospital.
Previously, Dr. Yacyshyn was a Gastrointestinal Category Leader (Medical Director) at Procter and Gamble Pharmaceuticals from 2005-2008. He has published over 150 articles, and written over five book chapters in the field of Gastroenterology. Dr. Yacyshyn is an expert in drug development in all clinical phases of drug development and has represented industry to the FDA and Health Canada as well as the EMA in Europe. He has been the gastrointestinal expert for industry for licensing and acquisition projects and was a member on the technical due diligence team for Procter and Gamble Pharmaceuticals.
Dr. Yacyshyn is a Distinguished Professor at Xiangya Institute of Translational Medicine, Central South University, China. He holds the prestigious thousand person award from the Chinese government for biotechnology and pharmaceutical development. He is a member of the FDA-related matters committee for the American College of Gastroenterology (ACG).
Dr Yacyshyn was awarded a TOP DOC award for Gastroenterology/Crohns disease in Cincinnati for 2014 by his peers, as recognized by Cinci Magazine.
Internal Medicine, Gastroenterology
> 20 yrs.
Time with Patients
76% - 100%
Patients per Month
Private plans, Medicare plans, Medicaid plans
Academic Medical Center
I conduct clinical trials
I have authored guidelines for care within my field
I speak at regional and/or national conferences
Professor of Medicine at University of Cincinnati (since Mar 2009)
Medical Director of Inpatient GI services at University of CIncinnati Hospital (Jan 2011 - Dec 2014)
Clinical Research, Innovation Development, Research Design, Treatment
Experience in phase 1-4 clinical trial design and supervision. PI on a number of Key studies. FDA experience. Industry experience. KOL status in IBD, C difficile and biomarker areas.
Translational research, Biomarker design, Difficult to recruit clinical trial design, Molecular medicine, Personalized medicine